Bipolar Disorder Channel
Topics & Medications
Related Channels

Abilify 15 mg Tablets

Abilify® (aripiprazole) is a medication approved for the treatment of depression, schizophrenia, autism, and bipolar disorder. It is available by prescription only and comes in several different forms and strengths, including:
  • Abilify 2 mg tablets
  • Abilify 5 mg tablets
  • Abilify 10 mg tablets
  • Abilify 15 mg tablets
  • Abilify 20 mg tablets
  • Abilify 30 mg tablets
  • Abilify Discmelt® 10 mg orally disintegrating tablets
  • Abilify Discmelt 15 mg orally disintegrating tablets
  • Liquid Abilify (containing 1 mg of Abilify per mL).
Adults with bipolar disorder typically start with Abilify 15 mg tablets (one tablet, once daily). If needed, your healthcare provider may increase your dosage up to 30 mg once a day. For children and adolescents ages 10 to 17, the recommended starting Abilify dose is 2 mg once daily.
The recommended starting Abilify dose for schizophrenia in adults is 10 mg to 15 mg once daily. For adolescents 13 to 17 years old, the recommended starting dosage is 2 mg once daily.
For the treatment of major depression, the recommended starting dose of Abilify is 2 mg to 5 mg once daily. The effective dose is usually Abilify 5 to 10 mg once daily.
For treating autism in children age 6 through 17, a starting dosage of Abilify 2 mg daily is usually recommended. If necessary, the child's healthcare provider may increase the dose up to 15 mg daily.
(Click Abilify Dosage for more details on when and how to take Abilify and to find out what factors your healthcare provider may consider before making a dosing recommendation.)
Healthy Pet, Healthy You
Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.